A Study of Tecogalan Sodium
Launched by DAIICHI PHARMACEUTICALS · Aug 30, 2001
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Kaposi's sarcoma plus HIV infection OR metastatic solid tumor.
- • Life expectancy of at least 12 weeks.
- • NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks.
- • Recovered from toxicity of any prior anticancer therapy.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- • Leukemia or lymphoma.
- • Current gastrointestinal bleeding by stool guaiac.
- • Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors.
- • Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics.
- • Acute intercurrent infection other than genital herpes.
- • Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy.
- Concurrent Medication:
- Excluded:
- • Other anticancer therapy.
- • Other investigational agents.
- Patients with the following prior conditions are excluded:
- • History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease.
- • History of myocardial infarction within past 6 months.
- Prior Medication:
- Excluded:
- • Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C).
- • Investigational agents within the past 4 weeks.
About Daiichi Pharmaceuticals
Daiichi Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs. With a strong emphasis on advancing healthcare through cutting-edge science and technology, the company focuses on a diverse range of therapeutic areas, including oncology, cardiovascular, and metabolic diseases. Committed to improving patient outcomes, Daiichi Pharmaceuticals leverages its extensive expertise and collaborative partnerships to drive clinical trials that explore novel treatment options and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials